Nolet Chris 4

What Happened
Chris Nolet, a director at ArriVent BioPharma, was granted a derivative award of 13,562 shares (reported as an acquisition, code A) on 2026-06-18. The grant is recorded at $0.00 per share (total $0 at issuance) because it is an equity award/option rather than a cash purchase. The Form 4 reporting the grant was filed on 2026-06-22.

Key Details

• Transaction date: 2026-06-18 (reported on Form 4 filed 2026-06-22)
• Transaction type/code: Grant / Award (A); derivative security (option/award)
• Amount: 13,562 shares (derivative) at $0.00 per share (value at grant $0)
• Vesting: Footnote F1 — underlying shares vest on the first anniversary of the grant date, subject to continued service through the vesting date.
• Shares owned after transaction: Not specified in the provided filing summary.
• Timeliness: Filed 6/22/2026 for a 6/18/2026 grant — within the standard Form 4 filing window (not reported late).

Context
This was a standard director equity award (non-cash compensation) that vests one year after grant if service continues. Because these are derivative awards that have not vested, they do not represent immediately tradable shares and should be interpreted as a compensation event rather than a direct buy or sell by the insider.